Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.87

-2.3%

Dec 5 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (3607)	4/27/2001 9:46:47 AM
From: rkrw	of 52153

I think the IPIC move may have been related to PFE mentioning pagoclone (licensed from IPIC): biz.yahoo.com ``Coming next,'' he said, ``are seven major late-stage development candidates, spanning major disease areas from diabetes to atherosclerosis.'' He detailed progress on three programs scheduled to conclude and be filed for regulatory review this year and next: Exubera or inhaled insulin, co-promoted with Aventis Pharma; pregabalin for treatment of neuropathic pain and epilepsy; and darifenacin for overactive bladder. The other late-stage candidates are lasofoxifene for treatment and prevention of osteoporosis; capravirine for HIV; pagaclone for panic and anxiety disorders; and avasimibe for atherosclerosis.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next